Fleseriu, M;
Buchfelder, M;
Cetas, JS;
Fazeli, PK;
Mallea-Gil, SM;
Gurnell, M;
McCormack, A;
... Marcus, HJ; + view all
(2020)
Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective.
Pituitary
, 23
pp. 327-337.
10.1007/s11102-020-01059-7.
(In press).
Preview |
Text
Pituitary society guidance pituitary disease management and patient care recommendations during the COVID-19 pandemic-an int.pdf - Published Version Download (654kB) | Preview |
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral strain that has caused the coronavirus disease 2019 (COVID-19) pandemic, has presented healthcare systems around the world with an unprecedented challenge. In locations with signifcant rates of viral transmission, social distancing measures and enforced ‘lockdowns’ are the new ‘norm’ as governments try to prevent healthcare services from being overwhelmed. However, with these measures have come important challenges for the delivery of existing services for other diseases and conditions. The clinical care of patients with pituitary disorders typically involves a multidisciplinary team, working in concert to deliver timely, often complex, disease investigation and management, including pituitary surgery. COVID-19 has brought about major disruption to such services, limiting access to care and opportunities for testing (both laboratory and radiological), and dramatically reducing the ability to safely undertake transsphenoidal surgery. In the absence of clinical trials to guide management of patients with pituitary disease during the COVID-19 pandemic, herein the Professional Education Committee of the Pituitary Society proposes guidance for continued safe management and care of this population.
Type: | Article |
---|---|
Title: | Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1007/s11102-020-01059-7 |
Publisher version: | https://doi.org/10.1007/s11102-020-01059-7 |
Language: | English |
Additional information: | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
Keywords: | SARS-CoV-2 · COVID-19 · Pituitary disease and surgery · Cushing’s disease · Acromegaly · Prolactinomas |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
URI: | https://discovery.ucl.ac.uk/id/eprint/10104900 |
Archive Staff Only
![]() |
View Item |